Filing Details
- Accession Number:
- 0001104659-18-002700
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-01-17 18:38:54
- Reporting Period:
- 2018-01-17
- Accepted Time:
- 2018-01-17 18:38:54
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1356576 | Supernus Pharmaceuticals Inc | SUPN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1539215 | P. Padmanabh Bhatt | C/O Supernus Pharmaceuticals, Inc. 1550 East Gude Drive Rockville MD 20850 | Sr. Vp Of Ip, Cso | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-01-17 | 20,000 | $7.90 | 32,500 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-01-17 | 20,000 | $44.98 | 12,500 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2018-01-17 | 20,000 | $0.00 | 20,000 | $7.90 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
60,000 | 2023-02-05 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 14, 2017.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.95 to $45.00, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted.